Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)
Authors:
- Robert F. StoreyRSRobert F. Storey
- Richard C. BeckerRBRichard C. Becker
- Robert A. HarringtonRHRobert A. Harrington
- Steen HustedSHSteen Husted
- Stefan K. JamesSJStefan K. James
- Frank CoolsFCFrank Cools
- Philippe Gabriel StegPSPhilippe Gabriel Steg
- Nardev S. KhurmiNKNardev S. Khurmi
- Hakan EmanuelssonHEHakan Emanuelsson
- Soo Teik LimSLSoo Teik Lim
- Christopher P. CannonCCChristopher P. Cannon
- Hugo A. KatusHKHugo A. Katus
- 1 December 2011
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 108 (11) , 1542-1546
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 9 references indexed in Scilit:
- Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET StudyJACC, 2010
- Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 2010
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery DiseaseCirculation, 2009
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialAmerican Heart Journal, 2009
- Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary SyndromesJACC, 2007
- Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary SyndromeJACC, 2007
- Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEuropean Heart Journal, 2006
- Intravenous adenosine and dyspnea in humansJournal of Applied Physiology, 2005